Showing 1 - 6 results of 6 for search 'Maria Zajac-Kaye', query time: 0.03s Refine Results
  1. 1
    PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

    PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer by Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou

    Published 2024-03-01
    Get full text
    Article
  2. 2
    Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival

    Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival by Vinod Vijayakurup, Kyungah Maeng, Hye Seung Lee, Benjamin Meyer, Sandra Burkett, Akbar Nawab, Michael W. Dougherty, Christian Jobin, Iqbal Mahmud, Timothy J. Garrett, Michael Feely, Kyoung Bun Lee, Frederic J. Kaye, Maria V. Guijarro, Maria Zajac-Kaye

    Published 2022-10-01
    Get full text
    Article
  3. 3
    Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice

    Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice by Sajid Khan, Patrick Kellish, Nick Connis, Dinesh Thummuri, Janet Wiegand, Peiyi Zhang, Xuan Zhang, Vivekananda Budamagunta, Nan Hua, Yang Yang, Umasankar De, Lingtao Jin, Weizhou Zhang, Guangrong Zheng, Robert Hromas, Christine Hann, Maria Zajac-Kaye, Frederic J. Kaye, Daohong Zhou

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy

    Corrigendum: Targeting thymidylate synthase enhances the chemosensitivity of triple-negative breast cancer towards 5-FU-based combinatorial therapy by Nair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, Nikhil Ponnoor Anto, Vijayasteltar B. Liju, Vijai V. Alex, Areekkara Nisthul Amrutha, Sreekumar U. Aiswarya, Mundanattu Swetha, Balachandran S. Vinod, Sankar Sundaram, Maria V. Guijarro, Thomas Herlevich, Archana Krishna, Nesteena K. Nestory, Smitha V. Bava, Chittalakkottu Sadasivan, Maria Zajac-Kaye, Ruby John Anto

    Published 2023-12-01
    Get full text
    Article
  5. 5
    Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy

    Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy by Nair Hariprasad Haritha, Akbar Nawab, Vinod Vijayakurup, Nikhil Ponnoor Anto, Vijayasteltar B. Liju, Vijai V. Alex, Areekkara Nisthul Amrutha, Sreekumar U. Aiswarya, Mundanattu Swetha, Balachandran S. Vinod, Sankar Sundaram, Maria V. Guijarro, Thomas Herlevich, Archana Krishna, Nesteena K. Nestory, Smitha V. Bava, Chittalakkottu Sadasivan, Maria Zajac-Kaye, Ruby John Anto

    Published 2021-07-01
    Get full text
    Article
  6. 6
    First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival

    First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival by Maria V. Guijarro, Patrick C. Kellish, Peter E. Dib, Nicholas G. Paciaroni, Akbar Nawab, Jacob Andring, Lidia Kulemina, Nicholas V. Borrero, Carlos Modenutti, Michael Feely, Elham Nasri, Robert P. Seifert, Xiaoping Luo, Richard L. Bennett, Daniil Shabashvili, Jonathan D. Licht, Robert McKenna, Adrian Roitberg, Robert W. Huigens III, Frederic J. Kaye, Maria Zajac-Kaye

    Published 2023-05-01
    Get full text
    Article

Search Tools: